Disclosed herein is a multicellular lay-up process. The process comprises the steps of: a) forming a core material, b) forming a capsule material, c) encapsulating the core with the capsule material, d) adding the capsule to a substrate, and e) exposing the capsule to at least one bioactivating agent.

The present disclosure provides an encapsulated liver tissue that can be used in vivo to improve liver functions, in vitro to determine the hepatic metabolism and/or hepatotoxicity of an agent and ex vivo to remove toxic compounds from patients' biological fluid. The encapsulated liver tissue comprises at least one liver organoid at least partially covered with a biocompatible cross-linked polymer. Processes for making the encapsulated liver tissue are also provided.

Provided herein are polymers of Formula (I), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, and isotopically labeled derivatives thereof, compositions, and formulations thereof. The polymers described herein are biocompatible, non-toxic, water compatible, and operationally simple to formulate. Also provided are methods and kits involving the polymers described herein (e.g., methods of using polymers described herein for delivering agents (e.g., for therapeutic, diagnostic, prophylactic, imaging, ophthalmic, intraoperative, or cosmetic use) to a subject, cell, tissue, or biological sample, as part of materials (e.g., biodegradable materials, biocompatible materials, wound dressing (e.g., bandages), drug depots, coatings), or as scaffolds for tissue engineering. Provided are methods for synthesizing the polymers described herein, and polymers described herein synthesized by the synthetic methods described herein. ##STR00001##

A modular engineered tissue construct includes a plurality of fused self-assembled, scaffold-free, high-density cell aggregates. At least one cell aggregate includes a plurality of cells and a plurality of biocompatible and biodegradable nanoparticles and/or microparticles that are incorporated within the cell aggregates. The nanoparticles and/or microparticles acting as a bulking agent within the cell aggregate to increase the cell aggregate size and/or thickness and improve the mechanical properties of the cell aggregate as well as to deliver bioactive agents.

The present disclosure provides biomaterials and methods for preventing and minimizing progression of cartilage and/or connective tissue damage. Also provided herein are biomaterials and methods for alleviating and/or reducing the risk for developing arthritis (e.g., osteoarthritis) associated with joint injury and/or joint surgery.

Methods of manufacturing dental prosthesis/implants each to replace a non-functional natural tooth positioned in a jawbone of a specific pre-identified patient are provided. An example method includes the steps of receiving imaging data such as x-ray image data and surface scan data of a dental anatomy and/or a physical impression of the dental anatomy of a specific preidentified patient. The steps can also include forming a three-dimensional virtual model of at least portions of a non-functional natural tooth positioned in the jawbone of the specific pre-identified patient based on the imaging and surface scan data, virtually designing a dental implant based upon the virtual model, exporting the data describing the designed dental implant to a manufacturing machine, and custom manufacturing the dental implant for the specific patient.

The present disclosure relates to methods of preparing personalized blood vessels, useful for transplantation with improved host compatibility and reduced susceptibility to thrombosis. Also provided are personalized blood vessels produced by the methods and use thereof in surgery.

The present disclosure provides methods for treating acute wounds and improving outcomes by applying to an acute wound a skin substitute that is an organotypic human skin equivalent comprising NIKS cells. In certain embodiments, the closed wound has improved vascularity, improved pigmentation, decreased thickness, decreased pain, increased pliability, increased surface area, decreased stiffness, decreased itching, improved color, or any combination thereof, as assessed by an observer or by the subject, as compared to an autograft or another skin substitute.

Implantable scaffolds that treat solid tumors and escape variants and that provide effective vaccinations against cancer recurrence are described. The scaffolds include genetically-reprogrammed lymphocytes and a lymphocyte-activating moiety.

The present disclosure provides biomaterials and methods for preventing and minimizing progression of cartilage and/or connective tissue damage. Also provided herein are biomaterials and methods for alleviating and/or reducing the risk for developing arthritis (e.g., osteoarthritis) associated with joint injury and/or joint surgery.